Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions.

Maximilian Marhold1, Andreas Heinzel2, Almas Merchant1

  • 1Department of Internal Medicine I - Division of Oncology, Comprehensive Cancer Center, Medical University of Vienna.

Journal of Visualized Experiments : Jove
|June 14, 2021
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of HER2 Expression Levels, Including HER2-Ultralow, in a Retrospective Male Breast Cancer Cohort.

Life (Basel, Switzerland)·2026
Same author

Donor bone marrow together with recipient regulatory T cells induces chimerism without irradiation in kidney transplantation.

Science translational medicine·2026
Same author

A systematic evaluation and benchmarking of text summarization methods for biomedical literature: From word-frequency methods to language models.

bioRxiv : the preprint server for biology·2026
Same author

HER2-directed therapy is associated with an increased rate of cardiologic emergency department visits in real-world breast cancer patients.

Breast (Edinburgh, Scotland)·2026
Same author

Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.

Nature communications·2026
Same author

Comparison of T-DXd-associated pulmonary toxicity in real-world settings and clinical trials.

NPJ breast cancer·2026

Synthetic lethal interactions offer new cancer therapy targets. This study presents a data integration workflow to identify effective drug combinations for targeting these interactions, with applications in ovarian and breast cancer.

Area of Science:

  • Genomics
  • Cancer Biology
  • Pharmacology

Background:

  • Synthetic lethality occurs when the combined loss of two genes leads to cell death, unlike the loss of either gene alone.
  • The BRCA1/2 and PARP1 interaction is a clinically validated example, with PARP1 inhibitors used for BRCA1/2-mutated cancers.
  • Numerous synthetic lethal pairs have been identified, presenting opportunities for novel cancer therapeutics.

Purpose of the Study:

  • To outline a data integration workflow for evaluating and identifying drug combinations targeting synthetic lethal interactions.
  • To leverage existing datasets for drug combination discovery in cancer therapy.
  • To assess drug combinations in the context of ovarian and breast cancer.

Main Methods:

  • Data integration of synthetic lethal interaction pairs, gene homology, drug-target links, and clinical trial information.

Related Experiment Videos

  • Utilizing dedicated databases for drug and target information.
  • Applying the workflow to assess drug combinations for ovarian and breast cancer.

    • Main Results:

    • The study outlines a comprehensive workflow for identifying potential drug combinations based on synthetic lethality.
    • Key findings from recent studies on drug combination assessment in ovarian and breast cancer are highlighted.
    • The workflow integrates diverse biological and pharmacological data for robust evaluation.

    Conclusions:

    • Synthetic lethal interactions represent a promising avenue for developing targeted cancer therapies.
    • The presented data integration workflow facilitates the identification of novel drug combinations for cancer treatment.
    • This approach has potential applications in precision medicine for ovarian and breast cancer.